Objective: Comprehensive analysis of ANAPC4 expression and its clinical relevance in hepatocellular carcinoma (HCC), with exploration of underlying mechanisms. Methods: The mRNA expression data sets of HCC in GEO, TCGA, SRA, GTEx, Oncomine and ArrayExpress databases were collected, and the mRNA expression level of ANAPC4 was analyzed. The protein expression intensity of ANAPC4 was observed by downloading ANAPC4 immunohistochemical staining pictures from the THPA database. The receiver operating characteristic curve(ROC), summary receiver operating characteristics, sensitivity, specificity, negative and positive likelihood ratios were used to evaluate the potential value of ANAPC4 in the differential diagnosis of HCC. Begg test was used to evaluate data publication bias. The expression level of ANAPC4 was further verified by single cell analysis, and the potential effect of ANAPC4 gene on the growth of HCC cell lines was analyzed by CRISPR knockout screening technology. Differentially related genes were used for GO and KEGG pathway enrichment analysis. Results: A total of 35 data sets (2 731 HCC tissues vs. 3 486 normal tissues) were included in the study. The pooled standardized mean difference (SMD) was 0.65(95%CI: 0.45-0.84), the area under the SROC curve was 0.79(95%CI: 0.75-0.83), the sensitivity was 0.62(95%CI: 0.50-0.72), and the specificity was 0.84(95%CI: 0.74-0.90). The positive likelihood ratio was 3.79(95%CI: 2.50-5.75), and the negative likelihood ratio was 0.46(95%CI: 0.36-0.58). Begg test suggested that there was no statistically significant publication bias. Single-cell sequencing data analysis revealed that ANAPC4 is significantly upregulated in HCC cells, which was further confirmed at the single-cell level. CRISPR-Cas9 knockout experiments demonstrated that ANAPC4 deletion markedly impaired the proliferative capacity of HCC cells. Notably, genes positively correlated with high ANAPC4 expression were significantly enriched in the cell cycle pathway. Conclusion: ANAPC4 is highly expressed in HCC and has a good ability to identify HCC, and may be involved in the occurrence and development of HCC through the cell cycle pathway.
WU Weizi
,
QIN Kai
,
ZHANG Guanlan
,
LIU Zhisu
,
CHEN Jitian
,
ZHAN Yanting
. The clinical significance and potential molecular mechanism of high expression of ANAPC4 in HCC[J]. Journal of Baotou Medical College, 2025
, 41(7)
: 75
-81
.
DOI: 10.16833/j.cnki.jbmc.2025.07.014
[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] Llovet JM, Kelley RK, Villanueva A, et al.Hepatocellular carcinoma[J].Nat Rev Dis Primers, 2021, 7(1):6.
[3] 曾红梅, 蔡建强.中国肝癌诊治现状再思考[J].肝癌电子杂志, 2021, 8(2):23-25.
[4] Nishida N.Long-term prognosis and management of hepatocellular carcinoma after curative treatment [J].Clin Mol Hepatol, 2020, 26(4):480-483.
[5] Kanwal F, Singal AG.Surveillance for hepatocellular carcinoma: current best practice and future direction [J].Gastroenterology, 2019, 157(1):54-64.
[6] Schrock MS, Stromberg BR, Scarberry L, et al.APC/C ubiquitin ligase:functions and mechanisms in tumorigenesis[J].Semin Cancer Biol, 2020, 67(Pt2):80-91.
[7] Watson ER, Brown NG, Peters JM, et al.Posing the APC/C E3 ubiquitin ligase to orchestrate cell division[J].Trends Cell Biol, 2019, 29(2):117-134.
[8] Lee CC, Li B, Yu H, et al.Sumoylation promotes optimal APC/C activation and timely anaphase[J].Elife, 2018, 7:e29539.
[9] Yatskevich S, Kroonen JS, Alfieri C, et al.Molecular mechanisms of APC/C release from spindle assembly checkpoint inhibition by APC/C SUMOylation[J].Cell Rep, 2021, 34(13):108929.
[10] Eifler K, Cuijpers SAG, Willemstein E, et al. SUMO targets the APC/C to regulate transition from metaphase to anaphase [J]. Nat Commun, 2018, 9(1): 1119.
[11] Wang L, Zhang J, Wan L, et al. Targeting Cdc20 as a novel cancer therapeutic strategy [J]. Pharmacol Ther, 2015, 151: 141-151.
[12] Zhao Y, Tang Q, Ni R, et al.Early mitotic inhibitor-1, an anaphase-promoting complex/cyclosome inhibitor, can control tumor cell proliferation in hepatocellular carcinoma: correlation with Skp2 stability and degradation of p27(Kip1)[J].Hum Pathol, 2013, 44(3):365-373.
[13] Li J, Gao JZ, Du JL, et al.Increased CDC20 expression is associated with development and progression of hepatocellular carcinoma [J].Int J Oncol, 2014, 45(4):1547-1555.
[14] Pacini C, Dempster JM, Boyle I, et al.Integrated cross-study datasets of genetic dependencies in cancer[J].Nat Commun.2021, 12(1):1661.
[15] Ho KH, Huang TW, Liu AJ, et al.Cancer essential genes stratified lung adenocarcinoma patients with distinct survival outcomes and identified a subgroup from the terminal respiratory unit type with different proliferative signatures in multiple cohorts[J].Cancers(Basel), 2021, 13(9):2128
[16] Shi M, Dai WQ, Jia RR, et al.APC(CDC20)-mediated degradation of PHD3 stabilizes HIF-1a and promotes tumorigenesis in hepatocellular carcinoma[J].Cancer Lett, 2021, 496:144-155.
[17] Huang Y, Zhu Y, Yang J, et al.CMTM6 inhibits tumor growth and reverses chemoresistance by preventing ubiquitination of p21 in hepatocellular carcinoma[J].Cell Death Dis, 2022, 13(3):251.
[18] Lara-Gonzalez P, Taylor SS.Cohesion fatigue explains why pharmacological inhibition of the APC/C induces a spindle checkpoint-dependent mitotic arrest [J].PLoS One, 2012, 7(11):e49041.
[19] De K, Grubb TM, Zalenski AA, et al.Hyperphosphorylation of CDH1 in glioblastoma cancer stem cells attenuates APC/C(CDH1) activity and pharmacologic inhibition of APC/C(CDH1/CDC20) compromises viability[J].Mol Cancer Res, 2019, 17(7):1519-1530.
[20] Lub S, Maes A, Maes K, et al.Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells [J].Oncotarget, 2016, 7(4):4062-4076.
[21] Gao Y, Zhang B, Wang Y, et al.Cdc20 inhibitor apcin inhibits the growth and invasion of osteosarcoma cells[J].Oncol Rep, 2018, 40(2):841-848.
